Literature DB >> 3023535

Restoration of wild-type pathogenicity to an attenuated DNA polymerase mutant of herpes simplex virus type 1.

B A Larder, J J Lisle, G Darby.   

Abstract

The drug-resistant variant, RSC-26, which was derived from the herpes simplex virus type 1 wild-type strain SC16, expresses an altered DNA polymerase and has reduced pathogenicity in animal models. To determine whether the attenuation in pathogenicity was due solely to mutation in the polymerase gene, a fragment of the wild-type gene was cloned, transferred into the genome of RSC-26 and recombinants were isolated. Three recombinants examined had similar properties to wild-type virus with respect to their sensitivity to antiviral drugs, DNA polymerase activities and their pathogenicity for mice. These results strongly suggest that expression of the altered polymerase of RSC-26 results in attenuated pathogenicity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3023535     DOI: 10.1099/0022-1317-67-11-2501

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  10 in total

Review 1.  Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  Isolation and characterization of herpes simplex virus mutants containing engineered mutations at the DNA polymerase locus.

Authors:  A I Marcy; D R Yager; D M Coen
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

3.  Identification of amino acids in herpes simplex virus DNA polymerase involved in substrate and drug recognition.

Authors:  J S Gibbs; H C Chiou; K F Bastow; Y C Cheng; D M Coen
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

4.  Identification, transfer, and characterization of cloned herpes simplex virus invasiveness regions.

Authors:  J L Goodman; M L Cook; F Sederati; K Izumi; J G Stevens
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

5.  Safety and efficacy of a thymidine kinase negative equine herpesvirus-1 vaccine in young horses.

Authors:  J Cornick; J Martens; R Martens; R Crandell; S McConnell; S Kit
Journal:  Can J Vet Res       Date:  1990-04       Impact factor: 1.310

6.  Changes in the bovine herpesvirus 1 genome during acute infection, after reactivation from latency, and after superinfection in the host animal.

Authors:  C A Whetstone; J M Miller; D M Bortner; M J Van der Maaten
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

7.  Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids.

Authors:  Julie Bestman-Smith; Guy Boivin
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

Review 8.  Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  J J O'Brien; D M Campoli-Richards
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

9.  Related functional domains in virus DNA polymerases.

Authors:  B A Larder; S D Kemp; G Darby
Journal:  EMBO J       Date:  1987-01       Impact factor: 11.598

10.  Pathogenicity of glycoprotein C negative mutants of herpes simplex virus type 1 for the mouse central nervous system.

Authors:  J C Sunstrum; C E Chrisp; M Levine; J C Glorioso
Journal:  Virus Res       Date:  1988-08       Impact factor: 3.303

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.